Citius Pharmaceuticals Inc. (NASDAQ:CTXR) saw an upside of 0.49% to $0.93 after adding $0.01 on Monday. The 5-day average trading volume is 1,295,506 shares of the company’s common stock. It has gained $0.9972 in the past week and touched a new high 2 times within the past 5 days. An average of 1,645,967 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,731,621.
CTXR’s 1-month performance is -22.88% or -$0.2711 on its low of $0.8502 reached on 07/31/23. The company’s shares have touched a 52-week low of $0.77 and high of $1.71, with the stock’s rally to the 52-week high happening on 04/17/23. YTD, CTXR has achieved 17.15% or $0.1389 and has reached a new high 17 times. However, the current price is down -45.88% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
CTXR stock has a beta of 1.40. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 1.49.
Citius Pharmaceuticals Inc.’s quick ratio for the period ended March 30 was 5.60, with the current ratio over the same period at 5.60.
Earnings Surprise
For the quarterly period ending March 30 this year, Citius Pharmaceuticals Inc.’s cash and short-term investments amounted to $40000.0 against total debt of $0.58 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 28.21% to -$10.53 million, while revenue of -$3.59 million was 65.91% off the previous quarter. Analysts expected CTXR to announce -$0.03 per share in earnings in its latest quarter, but it posted -$0.07, representing a -133.30% surprise. EBITDA for the quarter stood at more than -$10.64 million. CTXR stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 12.43 million, with total debt at $0.58 million. Shareholders hold equity totaling $158.86 million.
Let’s look briefly at Citius Pharmaceuticals Inc. (CTXR) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 04 August was 29.66% to suggest the stock is trending oversold, with historical volatility in this time period at 79.43%.
The stock’s 5-day moving average is $0.9393, reflecting a -6.16% or -$0.0610 change from its current price. CTXR is currently trading -23.86% above its 20-day SMA, -12.37% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -16.32% and SMA200 by-18.52%.
Stochastic %K and %D was 22.32% and 22.22% and the average true range (ATR) pointed at 0.0828. The RSI (14) points at 32.70%, while the 14-day stochastic is at 19.69% with the period’s ATR at 0.0824. The stock’s 9-day MACD Oscillator is pointing at -0.0593 and -0.1200 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Citius Pharmaceuticals Inc. (NASDAQ: CTXR), Maxim Group launched coverage with a Buy rating. Analysts offering their rating for CTXR stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate CTXR as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 3 have offered a “buy” rating.
What is CTXR’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $4.00 and a high of $8.00, with their median price target at $4.00. Looking at these predictions, the average price target given by analysts is for Citius Pharmaceuticals Inc. (CTXR) stock is $5.33.
